Patent · US Active

Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof

US9731031B2 · kind B2 · utility

13Cited by
7References
78Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 15, 2012
Grant dateAug 15, 2017
Priority date
Expiry dateJun 15, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.